Global Newsroom

^{_{CSL Behring Patient Zahra Khan, living with hereditary angioedema}}

Latest News

CSL Seqirus

Mar 10, 2026

CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas

CSL Seqirus will supply its differentiated influenza vaccine portfolio and, with long-term partner Sinergium Biotech, will localize vaccine filling and distribution. The partnership will...

Mar 9, 2026

CSL announces expansion of Illinois plasma therapy manufacturing facility

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived...

CSL Seqirus

Mar 5, 2026

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

FOR GLOBAL MEDIA CSL Seqirus will provide adjuvanted cell-based vaccines to support Canada, if an influenza pandemic is declared by the World Health Organization (WHO) Influenza viruses of...

CSL Seqirus

Feb 15, 2026

neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...

Dec 7, 2025

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic...

View All News

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.